Attached files

file filename
EX-31.2 - EXHIBIT 31.2 - Vaxart, Inc.ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - Vaxart, Inc.ex31-1.htm
EX-2.1 - EXHIBIT 2.1 - Vaxart, Inc.ex2-1.htm
EXCEL - IDEA: XBRL DOCUMENT - Vaxart, Inc.Financial_Report.xls
10-Q - FORM 10-Q - Vaxart, Inc.bota20150331_10q.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

 

In connection with the Quarterly Report on Form 10-Q of Biota Pharmaceuticals, Inc. (“the Company”) for the quarterly period ended March 31, 2015 (the “Report”), I, Joseph M. Patti, Chief Executive Officer of the Company, and Russell H. Plumb, Executive Chairman of the Company each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

 

To my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Dated: May 8, 2015 

By: 

/s/ Joseph M. Patti 

 

 

Joseph M. Patti 

 

 

Chief Executive Officer 

 

 

(Principal Executive Officer) 

 

 

 

 

 

 

 

By: 

/s/ Russell H Plumb 

 

 

Russell H Plumb 

 

 

Executive Chairman 

 

 

(Principal Financial Officer)